From May 22nd news release: The unique ex-vivo
Post# of 36537
(Total Views: 333)
Posted On: 07/17/2020 4:32:07 PM
From May 22nd news release:
The unique ex-vivo human immune system studies with convalescent blood samples will provide the data to select the best Ii-KeySARS-CoV-2 peptides for a “ Complete Vaccine ” that promotes B-Cell production of neutralizing antibodies and activates CD4+ T-Cell responses (TH1) that promote immune memory and potential long-term protection from coronavirus infection.
https://storage.googleapis.com/wzukusers/user...2_2020.pdf
The unique ex-vivo human immune system studies with convalescent blood samples will provide the data to select the best Ii-KeySARS-CoV-2 peptides for a “ Complete Vaccine ” that promotes B-Cell production of neutralizing antibodies and activates CD4+ T-Cell responses (TH1) that promote immune memory and potential long-term protection from coronavirus infection.
https://storage.googleapis.com/wzukusers/user...2_2020.pdf
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼